Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revefenacin Inhalation Solution in Moderate to Very Severe COPD – Phase 3 China
CTR20212308Phase 3Completed
- Sponsor
- Mylan
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Started Sep 2021; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20212308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212308.